TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03496857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting diode
Description: Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bath Therapy
Description: The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
Study: NCT02516410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661 plus ivacaftor combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-661 plus ivacaftor combination)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to ivacaftor)
Study: NCT00996931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 2.5 mgs per day orally for 12 weeks
Study: NCT04719234

Intervention type: DEVICE
Group type: OTHER
Intervention: lung ultrasonography
Description: Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
Study: NCT06098287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Residential mechanical ventilation system (Exhaust)
Description: Exhaust-only ventilation system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Residential mechanical ventilation system (CFIS) and air filtration upgrades
Description: Central-fan-integrated-supply ventilation system and air filtration upgrades (MERV 10)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Residential mechanical ventilation system (ERV) and air filtration upgrades
Description: Balanced energy recovery ventilation system and air filtration upgrades (MERV 10)
Study: NCT03440034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
Study: NCT02406222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy
Study: NCT03622073

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol treatment by Doctor
Description: Medical management of incomplete abortion
Study: NCT02031302

Intervention type: DEVICE
Intervention: Lotus Valve System
Description: The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] of \<1.0 cm2 or index of \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.

Intervention type: DEVICE
Intervention: Lotus Valve System
Description: The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] of \<1.0 cm2 or index of \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
Study: NCT03085355

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercises and PNE
Description: Exercise for stretching and strength for neck muscles and pain neuroscience education
Study: NCT01533077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg of BIA 9-1067 (single-dose)
Study: NCT03085355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Osteopathic manipulative treatment associated exercise for stretching and strength for neck muscles and pain neuroscience education
Study: NCT00258206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT03864068

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol
Description: 1gm/bid, 2gm/bid or 3gm/bid of Inositol powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol
Description: 1gm/bid, 2gm/bid or 3gm/bid of Inositol powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol
Description: 1gm/bid, 2gm/bid or 3gm/bid of Inositol powder
Study: NCT02999009

Intervention type: DEVICE
Group type: OTHER
Intervention: Trident II Tritanium Acetabular Shell
Description: A hemispherical acetabular shell indicated for cementless application.
Study: NCT00956384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-stage dermal matrix/implant procedure
Description: One-stage breast reconstruction with dermal matrix and implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage tissue expander/implant procedure
Description: Two-stage breast reconstruction with tissue expander and implant
Study: NCT00258206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT03882255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod dose range (2 - 20 mg)
Description: Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.
Study: NCT01574794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises
Description: The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
Study: NCT00300326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computer assist
Description: same implant using a computer-assisted surgical technique.
Study: NCT02312713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Based Exercise Training
Description: Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
Study: NCT01574794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle stretching exercise
Description: The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
Study: NCT03288753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire
Description: Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire
Description: Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech intelligibility in quiet
Description: The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech intelligibility in noise
Description: The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRB (Vocale Rapide dans le Bruit)
Description: Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
Study: NCT03775785

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailored enteral nutrition
Description: The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d.
Study: NCT03873896

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stimulated skin wrinkling test
Description: Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stimulated skin wrinkling test
Description: Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Nerve Block
Description: A digital nerve block is performed by injecting a total of 3 millilitres of 2% Lidocaine at the base of the ring finger of randomized hand of the volunteer. The effect of the block is confirmed clinically before proceeding with the study data collection. Please see the description for more details on the procedure
Study: NCT00761605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
Study: NCT01404871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomipramine
Description: oral tablets, starting at 50mg/daily for 12 weeks including \> 8 weeks at 250 mg/daily
Study: NCT03206684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
Study: NCT01404871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: oral tablet, starting 10mg/daily 12 week treatment including \>8 weeks at max dose 50mg daily
Study: NCT03206684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight\<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10\^9/L.
Study: NCT05142878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultracore Repose® mattress
Description: Residents will be placed on the Ultracore Repose® mattress during 14 days
Study: NCT02779634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ubiquinol
Description: Ubiquinol three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill three times daily
Study: NCT03882255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Propranolol
Description: Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Description: Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.
Study: NCT03041909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral drug
Study: NCT00679068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
Study: NCT02576873

Intervention type: OTHER
Intervention: Hemodiafiltration
Description: Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
Study: NCT02470702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (D5W)
Study: NCT03092479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
Study: NCT01578057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20mg, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20mg, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: 0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: 0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
Study: NCT03299322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jia Wei Yang He granule
Description: This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
Study: NCT01578057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tasimelteon
Description: once

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tasimelteon
Description: once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ethanol
Description: A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ethanol
Description: A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
Study: NCT00822484

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ILV-095

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05904184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoxy resin-based sealers (ERS)
Description: All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Epoxy resin-based sealers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium silicate-based sealers (CSS)
Description: All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Calcium silicate-based sealers.
Study: NCT01349686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diet
Description: Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fasting
Description: No intake of fluids during labour.
Study: NCT02598518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrating Combined Therapies
Description: Individual Integrating Combined Therapies, approximately 10 sessions, one session per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
Study: NCT04149639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NeuroQ
Description: Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
Study: NCT00695240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)
Description: Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
Study: NCT00946881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST 11 -mediated -VTP
Description: The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
Study: NCT01404871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: oral tablets, starting dose 30mg daily 12 week treatment including \>8weeks at 120mg daily
Study: NCT04443088

Intervention type: DRUG
Group type: OTHER
Intervention: INV-1120
Description: INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.
Study: NCT03299322

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jia Wei Yang He granule Placebo
Description: Made from 1/20 doses which has certain taste, but no therapeutic effect
Study: NCT01182337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradiscal rhGDF-5
Description: The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
Study: NCT03151252

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytobrush
Description: During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytobrush
Description: During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytobrush
Description: During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
Study: NCT01240148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3161
Description: Single dose, intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3161
Description: Single dose, intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3161
Description: Single dose, intradermal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Single dose, intradermal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD3161 Placebo
Study: NCT03060330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Laparoscopic Ventral Mesh Rectopexy
Description: This group will undergo modified laparoscopic ventral mesh rectopexy alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
Description: This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
Study: NCT04101760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting granulocyte colony stimulating factor
Description: Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-acting granulocyte colony stimulating factor
Description: Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns